906 results match your criteria: "Centre de Ressources[Affiliation]"
Mol Psychiatry
October 2024
MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others.
View Article and Find Full Text PDFLancet Reg Health Eur
September 2024
Department of NEUROFARBA, Unviersity of Florence, Florence, Italy.
Multiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central nervous system and a major cause of neurological disability in young adults. Its prevalence and incidence are increasing, and it has been estimated at over 2.8 million cases worldwide, in addition to recent trends towards a shift in MS prevalence to older ages, with peak prevalence estimates in the sixth decade of life.
View Article and Find Full Text PDFBMC Cancer
October 2024
Pediatric Onco-Hematology Department, University Hospitals of Strasbourg, 1 Avenue Molière, Strasbourg, France.
Thromb Res
November 2024
Université Paris Cité and Université Sorbonne Paris Nord, Inserm U1148-LVTS, Paris, France. Electronic address:
Autism Res
November 2024
Centre de Ressources Autisme Languedoc-Roussillon et Centre d'Excellence sur l'Autisme et les Troubles du Neurodéveloppement (CeAND), CHU Montpellier, Montpellier, France.
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition and understanding the changes in autism symptoms over time is crucial for tailoring support and interventions. This study therefore aimed to investigate the changes in symptom severity in a large cohort of children with ASD over a three-year follow-up period and identify factors that influence these changes. The study included 575 children diagnosed with ASD, ranging in age from 2 to 12 years, who were assessed at baseline and again 3 years later using the Autism Diagnostic Observational Schedule-2 (ADOS-2).
View Article and Find Full Text PDFPlant Methods
September 2024
School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
Waterlogging is expected to become a more prominent yield restricting stress for barley as rainfall frequency is increasing in many regions due to climate change. The duration of waterlogging events in the field is highly variable throughout the season, and this variation is also observed in experimental waterlogging studies. Such variety of protocols make intricate physiological responses challenging to assess and quantify.
View Article and Find Full Text PDFBMC Infect Dis
September 2024
Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.
Neurology
October 2024
From the Neurology Department (M.H., A.K., G.E., E.L.P., L. Michel), Rennes University Hospital; Clinical Neuroscience Centre (M.H., A.K., G.E., E.L.P., L. Michel), CIC_P1414 INSERM, Rennes, University Hospital, Rennes University; Université Claude Bernard Lyon 1 (F.R., R.C., S.V.), Université de Lyon; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation (F.R., R.C., S.V.), Hospices Civils de Lyon, Bron; Observatoire Français de la Sclérose en Plaques (F.R., R.C., S.V.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292; EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, state-approved foundation (F.R., R.C., S.V.), Bron; Department of Neurology (G.M.), Nancy University Hospital; Université de Lorraine (G.M.), Inserm, INSPIIRE, Nancy; MS Unit (P.L.), CHU de Montpellier; University of Montpellier (MUSE) (P.L.); Department of Neurology and Clinical Investigation Center (J.D.S.), CHU de Strasbourg, CIC 1434, INSERM 1434; Service de Neurologie (D.-A.L.), CHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CIC INSERM 1413; Department of Neurology (C.P.), Fondation Rotschild, Paris; Department of Neurology (T.M.), CHU de Dijon, EA4184; Department of Neurology (E.T.), Nimes University Hospital; IGF (E.T.), University of Montpellier, CNRS, INSERM; CHU de Caen (G.D.), MS Expert Centre, Department of Neurology, Normandy University, Caen; Neurology (C.L.-F.), UR2CA_URRIS, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice; Department of Neurology (J.C.), CHU de Toulouse, CRC-SEP; Université Toulouse III (J.C.), Infinity, INSERM UMR1291-CNRS UMR5051; Service de Neurologie (E.B.), CHU de Besançon; Sorbonne Universités (B.S.), Paris Brain Institute, ICM, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Hôpital de la Pitié Salpêtrière; CHU Clermont-Ferrand (P.C.), CRC SEP Auvergne, Department of Neurology, and INSERM NeuroDol U1107; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP; Centre de Ressources et de Compétences SEP Paris (E.M.); Departement of Neurology (O.H.), Centre de Ressource et Compétences SEP IDF Ouest, Hôpital de Poissy; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172; Department of Neurology (A.R.), University Hospital of Bordeaux; Neurocentre Magendie (A.R.), Bordeaux University, INSERM U1215; Department of Neurology (O.C.), CHU Grenoble Alpes, Neurology MS Clinic Grenoble, Grenoble Alpes University Hospital, La Tronche; Department of Neurology (S.M.), CHU de Reims, CRC-SEP; Department of Neurology (A.A.-K.), CHU d'Amiens; Departement of Neurology (B.B.), CHU de Rouen; Service de Neurologie (J.P.), Pôle de Neurosciences Cliniques, APHM, Hôpital de la Timone, Aix Marseille Univ; Department of Neurology (L. Magy), Hôpital Dupuytren, CHU de Limoges; Department of Neurology (J.-P.N.), Hôpital Jean Bernard, CHU La Milétrie, Poitiers; Department of Neurology (J.-P.C.), Hôpital Nord, CHU de Saint-Étienne; CRC SEP and Department of Neurology (I.D.), Hôpital Bretonneau, CHU de Tours; Department of Neurology (A.W.), Hôpital Henri Mondor, APHP, Créteil; Department of Neurology (M.T.), Hôpital Foch, Suresnes; Department of Neurology (C.L.), CHU Bicêtre; and Department of Neurology (K.H.), Hôpital Pierre Delafontaine, Centre Hospitalier de Saint-Denis, France.
JCI Insight
September 2024
Sorbonne Université, INSERM, Institut de Myologie, Centre de recherche en Myologie F-75013 Paris, France.
Thromb Haemost
October 2024
Department of Laboratory Medicine, Hematology Laboratory, CHU UCL Namur, Yvoir, Belgium.
Accurate assessment of platelet secretion is essential for the diagnosis of inherited or acquired platelet function disorders and more specifically in identifying δ-storage pool disease. Mepacrine, a fluorescent dye, specifically accumulates in platelet δ-granules. The mepacrine flow cytometry (mepacrine FCM) assay has been used for more than half a century in the clinical laboratory as a diagnostic tool for platelet δ-granule disorders.
View Article and Find Full Text PDFPLoS Pathog
September 2024
Institut Pasteur, Université Paris Cité, Biologie des Bactéries Intracellulaires, CNRS UMR 6047, Paris, France.
Legionella longbeachae and Legionella pneumophila are the most common causative agents of Legionnaires' disease. While the clinical manifestations caused by both species are similar, species-specific differences exist in environmental niches, disease epidemiology, and genomic content. One such difference is the presence of a genomic locus predicted to encode a capsule.
View Article and Find Full Text PDFAnn Clin Transl Neurol
November 2024
Normandie University, UNICAEN, INSERM, UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Institute Blood and Brain @Caen-Normandie (BB@C), GIP Cyceron, Caen, France.
Objective: Stroke is the leading cause of death and disability. Timely differentiation between ischemic stroke, hemorrhagic stroke, and stroke mimics is critical for tailored treatment and triage. To accelerate the identification of stroke's subtype, we propose to use the levels of circulating tPA as a biomarker.
View Article and Find Full Text PDFInfect Dis Now
October 2024
Centre d'Investigation Clinique Antilles Guyane, Inserm CIC 1424, Centre Hospitalier de Cayenne, Cayenne, French Guiana; DFR Santé, Université de Guyane, Cayenne, French Guiana.
Objectives: Management of Hepatitis B virus (HBV)-infected patients, whether they are receiving treatment or not, necessitates long-term follow-up. This study evaluated the rate of lost to follow-up (LTFU) among HBV-infected patients and the feasibility of a callback strategy to re-engage these patients in HBV care.
Patients And Methods: We conducted a retrospective study involving HBV-infected patients attending the outpatient clinic at Cayenne Hospital, French Guiana.
Nat Commun
September 2024
Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit, Paris, France.
The human gut virome, which is mainly composed of bacteriophages, also includes viruses infecting archaea, yet their role remains poorly understood due to lack of isolates. Here, we characterize a temperate archaeal virus (MSTV1) infecting Methanobrevibacter smithii, the dominant methanogenic archaeon of the human gut. The MSTV1 genome is integrated in the host chromosome as a provirus which is sporadically induced, resulting in virion release.
View Article and Find Full Text PDFKidney Int
December 2024
University Rouen Normandie, Institut national de la santé et de la recherche médicale (INSERM) U1096, Endothélium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France. Electronic address:
Kidney Int
November 2024
Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France; Department of Kidney Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address:
Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020.
View Article and Find Full Text PDFAnn Clin Microbiol Antimicrob
August 2024
Service de Microbiologie et Hygiène hospitalière, HydroSciences Montpellier, Univ. Montpellier, CNRS, IRD, CHU de Nîmes, Montpellier, 34093, France.
Background: Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the pathogens.
Objectives: We evaluated the performance of commercial tests for testing cefiderocol susceptibility in the Achromobacter genus and reviewed the literature.
Lancet Respir Med
November 2024
Université Paris-Cité, Institut Cochin, CNRS, INSERM, Paris, France; Respiratory Medicine and Cystic Fibrosis National Reference Center, Hôpital Cochin, AP-HP, Paris, France; ERN-Lung CF network, Frankfurt, Germany.
Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor-tezacaftor-ivacaftor for people with cystic fibrosis without a F508del CFTR variant in France and to determine CFTR variant responsiveness to elexacaftor-tezacaftor-ivacaftor based on the observed clinical response.
View Article and Find Full Text PDFAnn Biol Clin (Paris)
August 2024
Laboratoire de biologie médicale, Centre Hospitalier de Versailles, 122 rue de Versailles, 78157 Le Chesnay-Rocquencourt, France.
Emicizumab is a bispecific antibody that mimics the function of factor VIII (FVIII) and is indicated for prophylactic use in patients with congenital hemophilia A with or without inhibitors. Acquired hemophilia A (AHA) is a rare and severe disorder causes by autoantibodies that inhibit FVIII. In AHA, acute bleeding are managed with bypassing agents but several reports described the off-label use of emicizumab.
View Article and Find Full Text PDFNeurology
September 2024
From the Université Clermont Auvergne (X.M., C.C., P.C.), CHU Clermont-Ferrand, Inserm, Neuro-Dol; Univ Rennes (E.L.), EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309; Service de Neurologie (F.T.), CHU Clermont-Ferrand; Service de Neurologie (S.V.), Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Ressources, Recherche et Compétence sur la Sclérose en Plaques et Fondation Eugène Devic EDMUS pour la Sclé; and Biostatistics Unit (A.M.), DRCI, CHU Clermont-Ferrand, France.
Background And Objectives: People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection due to their level of motor disability or exposure to certain immunosuppressive treatments. Thus, patients with MS have had priority access to coronavirus disease 2019 (COVID-19) vaccination. However, relapses after vaccination have been reported, leading some patients to not seek the recommended booster doses.
View Article and Find Full Text PDFCells
July 2024
CHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, ITUN, 44000 Nantes, France.
The aim of our study was to determine whether granzyme B-expressing regulatory B cells (GZMB B cells) are enriched in the blood of transplant patients with renal graft tolerance. To achieve this goal, we analysed two single-cell RNA sequencing (scRNAseq) datasets: (1) peripheral blood mononuclear cells (PBMCs), including GZMB B cells from renal transplant patients, i.e.
View Article and Find Full Text PDFiScience
August 2024
Department of Immunology, Hôpital Européen Georges-Pompidou, Hôpital Necker Department of Immunology, Paris, France.
Coordinating immune responses - humoral and cellular - is vital for protection against severe Covid-19. Our study evaluates a multicytokine CD4T cell signature's predictive for post-vaccinal serological and CD8T cell responses. A cytokine signature composed of four cytokines (IL-2, TNF-α, IP10, IL-9) excluding IFN-γ, and generated through machine learning, effectively predicted the CD8T cell response following mRNA-1273 or BNT162b2 vaccine administration.
View Article and Find Full Text PDFInt J Cancer
January 2025
Université de Reims Champagne Ardenne, IRMAIC UR 7509, Reims, France.